|
Sign In to gain access to subscriptions and/or personal tools.
|
Identification of Novel Kv1.3 Blockers Using a Fluorescent Cell-Based Ion Channel Assay
Mark Slack
Evotec AG Schnackenburgallee 114 22525 Hamburg, Germany E-mail: Mark.Slack@evotec.com
Christian Kirchhoff
Clemens Moller
Dirk Winkler
Rainer Netzer
Afunctional cell-based assaywas developed using a generic proprietary assay protocol, based on a membrane-potential sensitive dye, for the identification of small-molecule antagonists against the Kv1.3 potassium ion channel. A high-throughput screen (HTS) was subsequently performed with 20,000 compounds from the Evotec library, preselected using known smallmolecule antagonists for both sodium and potassium ion channels. Following data analysis, the hit rate was measured at 1.72%, and subsequent dose-response analysis of selected hits showed a high hit confirmation rate yielding approximately 50 compounds with an apparent IC 50 value lower than 10 µ M. Subsequent electrophysiological characterization of selected hits confirmed the initial activity and potency of the identified hits on the Kv1.3 target and also selectivity toward Kv1.3 through measurements on HERG as well as Kv1.3-expressing cell lines. Follow-up structure-activity relationship analysis revealed a variety of different clusters distributed throughout the library as well as several singlicates. In comparison to known Kv1.3 blockers, newchemical entities and scaffolds showing potency and selectivity against the Kv1.3 ion channelwere detected. In addition, a screening strategy for ion channel drug discovery HTS, medicinal chemistry, and electrophysiology is presented.
Key Words: Kv1.3 • blocker • T lymphocytes • diabetes • ion channel
References
- Jentsch TJ, Huebner CA, Fuhrmann JC: Ion channels: Function unravelled by dysfunction. Nat Cell Biol2004;6:1039-1047.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ackermann MJ, Clapham DE: Ion channels: basic science and clinical disease. New Engl J Med1997;336:1575-1586.[Free Full Text]
- Coghlan MJ, Carroll WA, Gopalakrishan M: Recent Developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J Med Chem2001;44:1627-1653.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Anger T, Madge DJ, Mulla M, Riddall D: Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem2001;44:115-137.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Philipson LH, Hice RE, Schaefer K, LaMendola J, Bell GI, Nelson DJ, et al: Sequence and functional expression in Xenopus ooyctes of a human insulinoma and islet potassiumchannel. Proc Natl Acad Sci USA1991;88:53-57.[Abstract/Free Full Text]
- Attali B, Romey G, Honore E, Schmid-Alliana A, Mattei MG, Lesage F, et al: Cloning, functional expression, and regulation of two K+ channels in human T lymphocytes. J Biol Chem1992;267:8650-8657.[Abstract/Free Full Text]
- Szabo I, Bock J, Jekle A, Soddemann M, Adams C, Lang F, et al: Anovel potassium channel in lymphocyte mitochondria. J Biol Chem 2005;280:12790-12798.[Abstract/Free Full Text]
- Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, et al: Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol2005;67:1391-1381.[Abstract/Free Full Text]
- Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, et al: Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immuno1997;158:5120-5128.[Abstract]
- Xu J, Wang P, Li G, Li G, Kaczmarek LK, Wu Y, et al: The voltage-gated potassiumchannel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA2004;101:3112-3117.[Abstract/Free Full Text]
- Felix JP, Bugianesi RM, Schmalhofer WA, Borris R, Goetz MA, Hensens OD, et al: Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel Kv1.3. Biochemistry1999;38:4922-4930.[CrossRef][Medline]
[Order article via Infotrieve]
- Hill RJ, Grant AM, Volberg W, Rapp L, Faltynek C, Miller D, et al: WIN 17317-3: novel nonpeptide antagonist of voltage activated K+ channels in human T lymphocytes. Mol Pharmacol1995;48:98-104.[Abstract]
- Hanson DC, Nguyen A, Mather RJ, Rauer H, Koch K, Burgess LE, et al: UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltagegated potassium channel and inhibits human T-cell activation. Br J Pharmacol1999;126:1707-1716.[CrossRef][Medline]
[Order article via Infotrieve]
- Schmalhofer WA, Bao J, McManus OB, Green B, Matyskieda M, Wunderler D, et al: Identification of a new class of inhibitors of the voltage-gated potassium channel Kv1.3 with immunosuppressant properties. Biochemistry 2002;41:7781-7794.[CrossRef][Medline]
[Order article via Infotrieve]
- Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, et al: Kv1.3-blocking 5-phenylalkoyxpsoralens: a new class of immunomodulators. Mol Pharmacol2004;65:1364-1374.[Abstract/Free Full Text]
- Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hansel W, et al: Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem 2004;47:2326-2336.[CrossRef][Medline]
[Order article via Infotrieve]
- Zheng W, Spencer RH, Kiss L: High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol2004;2:543-552.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Xu J, Wang X, Ensign B, Li M, Wu L, Guia A, et al: Ion-channel assay technologies: quo vadis? Drug Disc Today2001;6:1278-1241.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wolff C, Fuks B, Chatelain P: Comparative study of membrane potentialsensitive fluorescent probes and their use in ion channel screening assays. J Biomol Screen2003;8:533-543.[Abstract/Free Full Text]
- Zhang S, Kehl SJ, Fedida D: Modulation of human ether-a-go-go related K+(HERG) channel inactivation by Cs+ and K+. JPhysiol2003;548:691-702.[Abstract/Free Full Text]
- Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patchclamp techniques for high-resolution current recording from cells and cellfree membrane patches. PFlugers Arch1981;391:85-100.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- "UNITY." St. Louis, MO: Tripos, 2002.
- Sammon JW: A nonlinear mapping for data structure analysis. IEEE Trans Comput1969;C-18:401-409.[CrossRef]
- Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.[Abstract/Free Full Text]
- Leonard RJ, Garcia ML, Slaughter RS, Reuben JP: Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA 1992;89:10094-10098.[Abstract/Free Full Text]
- Wulff H, Beeton C, Chandy KG: Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Disc Develop2003;6:640-647.
- Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.[Free Full Text]
This version was published on February
1, 2006
Journal of Biomolecular Screening, Vol. 11, No. 1,
57-64 (2006)
DOI: 10.1177/1087057105282712
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Y. Yount, D. Kupferwasser, A. Spisni, S. M. Dutz, Z. H. Ramjan, S. Sharma, A. J. Waring, and M. R. Yeaman
Selective reciprocity in antimicrobial activity versus cytotoxicity of hBD-2 and crotamine
PNAS,
September 1, 2009;
106(35):
14972 - 14977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zaks-Makhina, H. Li, A. Grishin, V. Salvador-Recatala, and E. S. Levitan
Specific and Slow Inhibition of the Kir2.1 K+ Channel by Gambogic Acid
J. Biol. Chem.,
June 5, 2009;
284(23):
15432 - 15438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
